- Home
- Industry Reports
- Diagnostics
- Healthcare
- Cancer Biomarkers Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Cancer biomarkers are used to trace and indicate the biological state of a tumour and thus analyse diagnostic and prognostic stages of cancer.The market is valued at USD 12.005 Billion in 2017 and is expected to reach USD 23.87 Billion by 2024 at a CAGR of 12.4%.
Cancer Biomarkers market share:
Cancer type segments cancer biomarkers market into breast cancer, lung cancer, colorectal cancer, melanoma, prostate, thyroid etc. over all these breast cancers is holding the most significant share in the market due to the prevalence of breast cancer and awareness about the diagnosis.
Cancer Biomarkers market size:
Geographically, North America is the dominant region globally, and the United States is the primary contributor. Asia-Pacific is expected to be the fastest growing regional market due to the prevalence of cancer in that region.
Cancer Biomarkers market growth:
The primary factors influencing the market growth an increase in awareness among patients and healthcare professionals about the necessity of early diagnostics of malignance’s and rising demand for personalised medicine is anticipated to provide the market with significant growth.
Cancer Biomarkers industry analysis:
The cancer biomarkers market is segmented by type, disease, service, application and technologies. From the kind, the market is categorised into protein biomarkers, genetic biomarkers, cell biomarkers, viral biomarkers, carbohydrate biomarkers. By disease, the market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer and cervical cancer. By service, the market is categorised into sample preparation, assay development, biomarkers validation and testing. By the application, the market is classified into risk assessment, development of molecular diagnostics, disease diagnostics, drug discovery and development. By technologies, the market is categorised into Omics technologies, imaging technologies, cytogenetics, bioinformatics and IVD multivariate index assays.
Cancer Biomarkers Market Outlook:
Cancer biomarkers are into various fields such as drug discovery, development, personalised medicine and diagnostics. Diagnostics is the essential revenue generating application of market relating to factors such as increasing growth of biomarker-based oncology tests with higher sensitivity.
Cancer Biomarkers Market Trends:
Abbott got new FDA labelling for some of its MRI active devices and announced the acquisition of st.jude medical, Inc. this transaction provides Abbott with expanded opportunities for future growth. Agilent technologies and multiplicon N.V signed an agreement under which Agilent will acquire multiplicon, a leading European diagnostics company.
Cancer Biomarkers Market Research Report Includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- HologicInc
- Abbott Laboratories
- Roche Diagnostics Corp.
- Agilent Technologies
- Astex Pharmaceuticals
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis0q
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Disease
6.1 Introduction
6.2 Prostate cancer
6.3 Lung cancer
6.4 Breast cancer
6.5 Cervical cancer
6.6 Colorectal cancer
Chapter 7 Market Segmentation by Application
7.1 Introduction
7.2 Risk assessment
7.2 Disease diagnostics
7.3 Development of Molecular Diagnostics
7.4 Drug formulation
7.5 Others
Chapter 8 Market Segmentation by Service
8.1 Introduction
8.2 Sample preparation
8.3 Assay development
8.4 Biomarkers validation and testing
Chapter 9 Market Segmentation by Type
9.1 Introduction
9.2 Protein biomarkers
9.3 Genetic biomarkers
9.4 Cell biomarkers
9.5 Viral Biomarkers
9.6 Carbohydrate biomarkers
Chapter 10 Market Segmentation by Technology
10.1 Introduction
10.2 Omics technologies
10.3 Cytogenetics
10.4 Imaging technologies
10.5 Immunoassays
10.6 Bioinformatics
10.7 IVD multivariate index assays
Chapter 11 Market Segmentation by Geography
11.1 North America
11.1.1 Introduction
11.1.2 United States
11.1.3 Canada
11.1.4 Mexico
11.1.5 Others
11.2 Europe
11.2.1 Introduction
11.2.2 France
11.2.3 Germany
11.2.4 Italy
11.2.5 United Kingdom
11.2.6 Spain
11.2.7 Russia
11.2.8 Others
11.3 Asia-pacific
11.3.1 Introduction
11.3.2 China
11.3.3 Japan
11.3.4 India
11.3.5 Australia
11.3.6 Others
11.5 Latin America
11.6.1 Introduction
11.6.2 Brazil
11.6.3 Argentina
11.6.4 Others
11.6 The Middle East and Africa
11.6.1 Introduction
11.6.2 Saudi Arabia
11.6.3 Israel
11.6.4 UAE
11.6.5 Others
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1 AffymetrixInc
13.2 HologicInc
13.3 Abbott Laboratories
13.4 Roche Diagnostics Corp.
13.5 Agilent Technologies
13.6 Astex Pharmaceuticals
13.7 Gen-Probe Inc
13.8 Atossa Genetics
13.9 Ambry Genetics
13.10 Thermo Fisher Scientific
13.11 Becton, Dickinson and Company
13.12 Danaher Corporation
13.13 GE Healthcare
13.14 Quest Diagnostics
13.15 Myriad Genetics
13.16 Biomérieux SA
13.17 Bio-Rad Laboratories
Chapter 14 Market Insights
14.1 Insights of Industry Experts
14.42 Analyst Opinion (Market Understanding)
14.3 Investment Opportunities
Chapter 15 Appendix
15.1 List of Tables
15.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,528.33 - €7,584.98
- INR: ₹225,496.39 - ₹676,489.18
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,164.96 - £6,494.87
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Cancer biomarkers are used to trace and indicate the biological state of a tumour and thus analyse diagnostic and prognostic stages of cancer.The market is valued at USD 12.005 Billion in 2017 and is expected to reach USD 23.87 Billion by 2024 at a CAGR of 12.4%.
Cancer Biomarkers market share:
Cancer type segments cancer biomarkers market into breast cancer, lung cancer, colorectal cancer, melanoma, prostate, thyroid etc. over all these breast cancers is holding the most significant share in the market due to the prevalence of breast cancer and awareness about the diagnosis.
Cancer Biomarkers market size:
Geographically, North America is the dominant region globally, and the United States is the primary contributor. Asia-Pacific is expected to be the fastest growing regional market due to the prevalence of cancer in that region.
Cancer Biomarkers market growth:
The primary factors influencing the market growth an increase in awareness among patients and healthcare professionals about the necessity of early diagnostics of malignance’s and rising demand for personalised medicine is anticipated to provide the market with significant growth.
Cancer Biomarkers industry analysis:
The cancer biomarkers market is segmented by type, disease, service, application and technologies. From the kind, the market is categorised into protein biomarkers, genetic biomarkers, cell biomarkers, viral biomarkers, carbohydrate biomarkers. By disease, the market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer and cervical cancer. By service, the market is categorised into sample preparation, assay development, biomarkers validation and testing. By the application, the market is classified into risk assessment, development of molecular diagnostics, disease diagnostics, drug discovery and development. By technologies, the market is categorised into Omics technologies, imaging technologies, cytogenetics, bioinformatics and IVD multivariate index assays.
Cancer Biomarkers Market Outlook:
Cancer biomarkers are into various fields such as drug discovery, development, personalised medicine and diagnostics. Diagnostics is the essential revenue generating application of market relating to factors such as increasing growth of biomarker-based oncology tests with higher sensitivity.
Cancer Biomarkers Market Trends:
Abbott got new FDA labelling for some of its MRI active devices and announced the acquisition of st.jude medical, Inc. this transaction provides Abbott with expanded opportunities for future growth. Agilent technologies and multiplicon N.V signed an agreement under which Agilent will acquire multiplicon, a leading European diagnostics company.
Cancer Biomarkers Market Research Report Includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- HologicInc
- Abbott Laboratories
- Roche Diagnostics Corp.
- Agilent Technologies
- Astex Pharmaceuticals
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis0q
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Disease
6.1 Introduction
6.2 Prostate cancer
6.3 Lung cancer
6.4 Breast cancer
6.5 Cervical cancer
6.6 Colorectal cancer
Chapter 7 Market Segmentation by Application
7.1 Introduction
7.2 Risk assessment
7.2 Disease diagnostics
7.3 Development of Molecular Diagnostics
7.4 Drug formulation
7.5 Others
Chapter 8 Market Segmentation by Service
8.1 Introduction
8.2 Sample preparation
8.3 Assay development
8.4 Biomarkers validation and testing
Chapter 9 Market Segmentation by Type
9.1 Introduction
9.2 Protein biomarkers
9.3 Genetic biomarkers
9.4 Cell biomarkers
9.5 Viral Biomarkers
9.6 Carbohydrate biomarkers
Chapter 10 Market Segmentation by Technology
10.1 Introduction
10.2 Omics technologies
10.3 Cytogenetics
10.4 Imaging technologies
10.5 Immunoassays
10.6 Bioinformatics
10.7 IVD multivariate index assays
Chapter 11 Market Segmentation by Geography
11.1 North America
11.1.1 Introduction
11.1.2 United States
11.1.3 Canada
11.1.4 Mexico
11.1.5 Others
11.2 Europe
11.2.1 Introduction
11.2.2 France
11.2.3 Germany
11.2.4 Italy
11.2.5 United Kingdom
11.2.6 Spain
11.2.7 Russia
11.2.8 Others
11.3 Asia-pacific
11.3.1 Introduction
11.3.2 China
11.3.3 Japan
11.3.4 India
11.3.5 Australia
11.3.6 Others
11.5 Latin America
11.6.1 Introduction
11.6.2 Brazil
11.6.3 Argentina
11.6.4 Others
11.6 The Middle East and Africa
11.6.1 Introduction
11.6.2 Saudi Arabia
11.6.3 Israel
11.6.4 UAE
11.6.5 Others
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1 AffymetrixInc
13.2 HologicInc
13.3 Abbott Laboratories
13.4 Roche Diagnostics Corp.
13.5 Agilent Technologies
13.6 Astex Pharmaceuticals
13.7 Gen-Probe Inc
13.8 Atossa Genetics
13.9 Ambry Genetics
13.10 Thermo Fisher Scientific
13.11 Becton, Dickinson and Company
13.12 Danaher Corporation
13.13 GE Healthcare
13.14 Quest Diagnostics
13.15 Myriad Genetics
13.16 Biomérieux SA
13.17 Bio-Rad Laboratories
Chapter 14 Market Insights
14.1 Insights of Industry Experts
14.42 Analyst Opinion (Market Understanding)
14.3 Investment Opportunities
Chapter 15 Appendix
15.1 List of Tables
15.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.